| アブストラクト | BACKGROUND/OBJECTIVES: Sodium-glucose cotransporter-2 inhibitors (SGLT2Is) were initially prescribed with caution due to potential adverse effects, including hypoglycemia, ketoacidosis, dehydration, and genital or urinary tract infections. However, reports of their organ-protective effects, including anti-inflammatory and anti-fibrotic actions, have emerged, suggesting a shift in the patient population receiving these medications. We aimed to analyze the temporal changes in this population. METHODS: This study is descriptive and retrospective in nature. We used claims data from the DeSC Healthcare Inc. to identify patients diagnosed with diabetes mellitus between October 2014 and February 2023 who had not received SGLT2Is for at least 6 months. Patients who subsequently received an SGLT2I prescription were categorized as SGLT2I users, and the overall population was defined. A subgroup of older patients (aged >/= 65) was also selected for analysis. Descriptive statistics were performed on the year of SGLT2I initiation, the proportion of patients with comorbidities, age, diabetes treatment history, and demographic data. RESULTS: The overall population included 347,195 patients. The proportion of patients with comorbidities increased by approximately 34%, from 21.0% in 2014-2016 to 54.8% in 2022. Additionally, the average age increased by approximately 15 years, from 62.0 +/- 11.7 to 76.6 +/- 11.2 years. The proportion of SGLT2I prescription for patients not currently undergoing treatment grew from 6.2% in 2014-2016 to 30.3% in 2022. In the older subgroup (275,833 patients), the average age progressed from 73.9 +/- 7.7 to 81.5 +/- 7.0 years, with patients not currently undergoing treatment increasing from 4.0 to 30.7%. CONCLUSIONS: SGLT2I use has expanded to older, high-risk patients with comorbidities, necessitating increased caution during prescription. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13340-025-00857-3. |
|---|
| 組織名 | Department of Public Health and Epidemiology, Meiji Pharmaceutical University,;2-522-1 Noshio, Kiyose-shi, Tokyo 204-8588 Japan. ROR: https://ror.org/00wm7p047.;GRID: grid.411763.6. ISNI: 0000 0001 0508 5056;Center for Experiential Pharmacy Practice, Faculty of Pharmacy, Tokyo University;of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392 Japan.;ROR: https://ror.org/057jm7w82. GRID: grid.410785.f. ISNI: 0000 0001 0659 6325 |
|---|
